SCHEMBL1756196

SCHEMBL1756196

COC(=O)C(NC(=O)c1nc(-c2ccc(N)cc2)cs1)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 1/20 0.46
MASP2 O00187 1/20 0.43
F2 P00734 1/20 0.43
ALDH1A1 P00352 6/20 0.42
NPC1 O15118 6/20 0.42
RAB9A P51151 6/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
MAPT P10636 3/20 0.42
LMNA P02545 2/20 0.42
TP53 P04637 2/20 0.42
MAPK1 P28482 2/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
POLB P06746 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALOX5 P09917 1/20 0.40
ATP4A P20648 2/20 0.38
ATP4B P51164 2/20 0.38
ITGB3 P05106 1/20 0.38
ITGA2B P08514 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1756255 0.84 LMNA (0.55) TACR3ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL1756202 0.82 MEN1 (0.52) ALDH1A1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL11969065 0.82 MEN1 (0.52) ALDH1A1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL1756223 0.80 MEN1 (0.53) TACR3MASP2F2ALDH1A1NPC1
SCHEMBL1756205 0.80 CSGALNACT1 (0.53) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL1756219 0.80 DGAT1 (0.57) TACR3ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL1756315 0.80 DGAT1 (0.57) ALDH1A1NPC1RAB9AMAPTMAPK1
SCHEMBL1756198 0.80 MASP2 (0.44) MASP2F2ALDH1A1NPC1RAB9A
SCHEMBL2294519 0.79 HPGDS (0.47) TACR3ALDH1A1NPC1RAB9ATAS1R3
SCHEMBL2294525 0.79 HPGDS (0.47) TACR3ALDH1A1NPC1RAB9ATAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722901-B2 Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity Piramal Enterprises Limited (IN) 2014-05-13 US disclosed
EP-2496564-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS Piramal Life Sciences Limited (IN) 2012-09-12 EP disclosed
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY Piramal Enterprises Limited (IN) 2012-08-23 US disclosed
WO-2011055289-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY DGAT1, DGAT2, DLAT TACR3 3181/4885MASP2 4503/4885F2 4324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.